EyePoint: DURAVYU's Durability Could Drive Significant Upside

AI Briefing

• – DURAVYU has shown a durable efficacy profile in Phase 2 clinical trials.
• – The company's lead candidate holds significant potential for treating wet AMD and DME.
• – Investors should consider EYPT stock as a potential long-term buy opportunity.